ONCOLYTIC VIRUS VS
IMMUNOTHERAPY
Checkpoint inhibitors remove brakes. Oncolytic viruses start the engine. They address different steps in the same failure of anti-tumour immunity β not competing for the same clinical role.
Different Problems, Different Tools
A cold tumour has no meaningful T-cell infiltration. Checkpoint inhibitors have nothing to release. In these tumours β the majority of solid tumour presentations β checkpoint inhibitor monotherapy response rates are consistently low. Viral infection changes the microenvironment through immunogenic cell death, dendritic cell recruitment, and T-cell activation. The cold tumour becomes hot. Now checkpoint inhibitors have T cells to work on.
βThe combination logic writes itself: initiation through viral infection, suppression removal through checkpoint inhibition. Two sequential barriers in the same pathway, addressed by two different mechanisms.β
Key Combination Data
- 62%ORR (T-VEC + pembrolizumab)Phase Ib/II first-line unresectable melanoma.
- 33%Complete Response RateT-VEC + pembrolizumab combination.
- 39% vs 18%ORR: T-VEC+ipi vs ipi alonePhase II combination vs ipilimumab monotherapy.
Patient Selection for Combination
The patients most likely to benefit from adding an oncolytic virus to checkpoint inhibitor therapy are cold tumour, PD-L1-negative, prior checkpoint inhibitor-naive patients. This criterion is guiding clinical practice at specialised melanoma centres. Biomarker divergence is important: PD-L1, TMB, and MSI predict checkpoint inhibitor response but are largely irrelevant for predicting oncolytic virus response.
Frequently Asked Questions
Combination Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Interested in Oncolytic Virus vs Immunotherapy?
Upload your medical reports for a free evaluation. Our team will identify the most relevant oncolytic virus programmes and clinical trials for your specific diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.